An Oxford spin-out developing targeted therapies for myeloproliferative neoplasms.
概要
Alethio Therapeutics is a biopharmaceutical company spun out of the University of Oxford. Its lead candidate ATX-011 is a monoclonal antibody that targets G6b and is being developed for essential thrombocythemia, a type of myeloproliferative neoplasm.